Related Experiment Videos
Plasma concentrations of misonidazole
Strahlentherapie
|January 1, 1980
Summary
This study analyzed misonidazole plasma concentrations, finding peak levels at 2 hours and dose-dependent increases. Misonidazole half-life varied by sex, with good linearity observed between drug doses and plasma levels.
Area of Science:
- Pharmacokinetics
- Clinical Pharmacology
- Drug Metabolism
Background:
- Misonidazole is a hypoxic cell radiosensitizer used in cancer therapy.
- Understanding its pharmacokinetic profile is crucial for optimizing treatment efficacy and safety.
Purpose of the Study:
- To analyze the plasma concentrations of misonidazole following single-dose administration.
- To investigate the variability in misonidazole plasma levels within and between patients.
- To determine the relationship between misonidazole dose and plasma concentration.
Main Methods:
- Plasma samples were collected from patients after administration of misonidazole doses ranging from 0.6 to 2.0 g/m2.
- Misonidazole concentrations were quantified using validated analytical methods.
- Pharmacokinetic parameters, including peak plasma levels, time to peak, half-life, and dose-concentration linearity, were calculated.
Main Results:
- Peak plasma concentrations of misonidazole were achieved approximately 2 hours post-administration.
- Mean plasma concentrations at 3 hours were 23.8, 47.0, and 76.5 microgram/ml for doses of 0.6, 1.2, and 2.0 g/m2, respectively.
- The elimination half-life of misonidazole was approximately 8.2 hours in women and 10.5 hours in men.
- A good linear correlation was observed between misonidazole doses and plasma levels within the studied range.
Conclusions:
- Misonidazole exhibits dose-proportional pharmacokinetics within the 0.6 to 2.0 g/m2 dose range.
- Sex influences misonidazole elimination half-life.
- These findings support the use of misonidazole in clinical settings with predictable plasma concentration profiles.